Jayme Heim, MSN, a Family Nurse Practitioner for West Michigan Dermatology and Clinical Manager of the Psoriasis and Eczema Treatment Center, recently spoke about the advancements in the dermatology field in relation to atopic dermatitis and psoriasis.
Regarding the announcement made by Arcutis Biotherapeutics, Inc. about their supplemental New Drug Application (sNDA) for roflumilast cream 0.15% for atopic dermatitis, Heim expressed her enthusiasm. She acknowledged the limited options available for patients with atopic dermatitis and highlighted the importance of this new medication in improving their quality of life.
Heim also emphasized the lack of understanding from insurance companies regarding the significance of these medications for patients. She stressed the importance of having a normalized skin barrier and the positive impact it can have on patients’ daily functioning and overall well-being.
Addressing the misconception that atopic dermatitis is a less impactful condition compared to others, Heim debunked this myth. She highlighted the efforts of organizations like the National Psoriasis Foundation in raising awareness about psoriasis and emphasized that these conditions are not just simple skin irritations but actual physical conditions with psychological implications.
The discussion then shifted to the use of brodalumab in treating psoriasis. Heim emphasized the need for adequate treatment for patients with psoriasis, as untreated or inadequately treated psoriasis can significantly affect patients’ mental health. While brodalumab is considered an effective medication, Heim acknowledged the challenges in transitioning patients from previous treatments to brodalumab and the availability of generic alternatives.
Overall, these recent developments in the dermatology field offer hope for patients with atopic dermatitis and psoriasis. The introduction of new medications and a better understanding of the impact of these conditions on patients’ lives are promising steps forward.
Sources:
– Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older.
– Andersch-Björkman, Y, Micu, E, Seifert, O, Lonne-Rahm, S-B, Gillstedt, M, Osmancevic, A. Effects of brodalumab on psoriasis and depressive symptoms in patients with insufficient response to TNF-α inhibitors. J Dermatol. 2023; 00: 1–14.
